Stocklytics Platform
Asset logo for symbol ALLO
Allogene Therapeutics
ALLO46
$2.83arrow_drop_down7.21%-$0.22
Penny Stock
Asset logo for symbol ALLO
ALLO46

$2.83

arrow_drop_down7.21%
Key Stats
Open$3.41
Prev. Close$3.42
EPS-1.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$714.04M
PE Ratio-
LOWHIGH
Day Range2.91
3.50
52 Week Range2.01
5.78
Ratios
Revenue-
EBITDA Margin %-
EPS-1.78
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.93%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ALLOarrow_drop_up18.29%
US Healthcare Sectorarrow_drop_up1.77%
US Marketarrow_drop_up1.10%
check_circle
ALLO / Market
ALLO exceeded the US Market which returned 1.10% over the last twenty four hours.
check_circle
ALLO / Healthcare Sector
ALLO exceeded the US Healthcare sector which returned 1.77% over the last twenty four hours.

Allogene Therapeutics (ALLO) Statistics

Allogene Therapeutics Inc (ALLO) is a biotechnology company focused on developing innovative allogeneic CAR T cell therapies for cancer treatment. As of the latest statistics, ALLO has a market capitalization of $X billion, with a price-to-sales ratio of X and a price-to-earnings ratio of X. These valuation metrics indicate the market's perception of the company's growth potential and overall financial performance. The fundamentals of ALLO are also strong, with a robust pipeline of CAR T cell therapies in various stages of development.

ALLO's stock performance has been impressive when compared to the sector. Over the past year, ALLO stock has generated a return of X%, outperforming the sector average of X%. This highlights the company's ability to deliver value to its shareholders. In terms of revenue per share, ALLO has reported $X in the latest financial period. This metric provides insight into the company's ability to generate revenue on a per-share basis, which is important for assessing its profitability. Furthermore, ALLO's Enterprise to EBITDA ratio stands at X, indicating its ability to generate operating income relative to its enterprise value.

add Allogene Therapeutics  to watchlist

Keep an eye on Allogene Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Allogene Therapeutics (ALLO) stock's performance compared to its sector and the market over the past year?

Over the past year, Allogene Therapeutics (ALLO) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, Allogene Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights Allogene Therapeutics 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Allogene Therapeutics (ALLO) stock?

The PE ratio for Allogene Therapeutics (ALLO) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Allogene Therapeutics (ALLO) stock?

The Earnings Per Share (EPS) for Allogene Therapeutics (ALLO), calculated on a diluted basis, is -$1.78. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Allogene Therapeutics (ALLO) stock?

The operating margin for Allogene Therapeutics (ALLO) is -315.93K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Allogene Therapeutics (ALLO) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Allogene Therapeutics (ALLO) is -$270.66M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Allogene Therapeutics (ALLO) have?

Allogene Therapeutics (ALLO) has a total debt of $95.85M. The net debt, which accounts for cash and cash equivalents against the total debt, is $44.81M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level